Tekcapital acquires patent application for new blood glucose testing technology

An Aim-listed company called Tekcapital has acquired the exclusive license to a US patent application for non-invasive glucose measuring in saliva.
People with diabetes have to prick their finger up to several times a day in order to test their blood glucose levels. But this groundbreaking technology could offer a painless alternative to blood glucose testing for people with diabetes, and does not penetrate the skin.
The technology, which was developed by Arizona State University, measures glucose levels using a safe, fast and non-invasive method.
Disposable biosensor strips collect a sample of saliva for both humans and animals, and the biosensor device traces samples for electrochemical analysis. This analysis then calculates blood glucose levels.
Tekcapital, an intellectual property portfolio builder, believes that this technology can bring an end to daily finger pricking for people with diabetes, which is the most commonly-used method of measuring blood glucose levels.
Dr. Clifford Gross, executive chairman of Tekcapital, said: “This is a step forward in non-invasive, glucose measurement. If commercialised successfully, this new technology could encourage patients and pet owners to measure blood sugar levels more frequently and without discomfort.”
This new research adds to the growing list of encouraging technological developments in which people with diabetes could monitor their blood glucose levels.